Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01816646 · ClinicalTrials.gov registry record · Phase 1
Intravesical Cidofovir for Hemorrhagic Cystitis
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01816646: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01816646 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01816646, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how the drug cidofovir given as 1 dose directly into the bladder is absorbed by the body. Researchers also want to measure the amount of study drug in the body at different time points. The safety and tolerability of this drug will also be studied. Cidofovir is designed to fight certain viruses by blocking the virus cells from dividing.
Interventions
- DRUG Probenecid
- DRUG Cidofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01816646
The ClinicalTrials.gov registry entry for NCT01816646 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Probenecid is the first listed.
NCT01816646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01816646 about?
NCT01816646 is a clinical study titled "Intravesical Cidofovir for Hemorrhagic Cystitis". The goal of this clinical research study is to learn how the drug cidofovir given as 1 dose directly into the bladder is absorbed by the body. Researchers also want to measure the amount of study drug in the body at different time points. The safety and tolerability of this drug will also be studied...
What is the current status of trial NCT01816646?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-09. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01816646?
The interventions under investigation include: Probenecid (DRUG), Cidofovir (DRUG).
Who is sponsoring clinical trial NCT01816646?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.